Corporate Board Profile
Tech Score: 14/100
1 mention(s) identify KENNETH I. KAITIN as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| CURIS INC | 2008-04-11 | Dr. Kaitin serves as a director of Phase Forward Inc., a software company that provides data management solutions for clinical trials and drug safety. Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. | Director of a software company providing data management solutions and has a Ph.D. in pharmacology, indicating technical expertise. |
| Filing Date | Source Excerpt |
|---|---|
| 2004-04-22 | Dr. Kaitin is Director of the Tufts Center for the Study of Drug Development and has a B.S., M.S., and Ph.D. in pharmacology. |
| 2005-04-20 | Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. |
| 2006-04-13 | Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. |
| 2007-04-13 | Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. |
| 2008-04-11 | Dr. Kaitin serves as a director of Phase Forward Inc., a software company that provides data management solutions for clinical trials and drug safety. Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. |
| 2009-04-17 | Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. |
| 2010-04-16 | Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. We believe that Dr. Kaitin’s qualifications to serve on our board include his expertise in the economics of drug development and biopharmaceutical innovation, his extensive knowledge on a broad range of drug development and life-sciences industry issues, and his experience as a director of other public companies. |
Data sourced from SEC filings. Last updated: 2026-02-03